Who
Andrew S. Boyer
Executive Vice President
Company insider
Files Form 4 as: Executive Vice President, Amneal Pharmaceuticals; SVP,Sales&Mktg,US Generics, Watson Pharmaceuticals.
In numbers
- Trades disclosed
- 159
- Buys
- 2
- Sells
- 6
- Bought
- $372K
- Sold
- $4.6M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Sep 2006
- Last trade
- 1 Sep 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 2 Sep 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —80,000 at $0.00 | filing |
| 1 Sep 2026filed 2 Sep 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —80,000 at $0.00 | filing |
| 21 Aug 2026filed 25 Aug 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —152,426 at $0.00 | filing |
| 21 Aug 2026filed 25 Aug 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —152,426 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $255K19,136 at $13.30 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —38,195 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —38,195 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —38,195 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $255K19,136 at $13.30 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —38,195 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —39,252 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —39,252 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —49,694 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —24,258 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —397,554 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $265K19,945 at $13.31 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —49,694 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —39,252 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —49,694 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —24,258 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.